Latest Advances

  • Journal: The Egyptian journal of immunology
  • Published —
CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients.
  • Journal: Frontiers in immunology
  • Published —
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
  • Journal: La Medicina del lavoro
  • Published —
Exposure to glyphosate and risk of non-Hodgkin lymphoma: an updated meta-analysis.
  • Condition: Patients with Chronic Lymphocytic Leukemia (CLL) in UK and Ireland
  • Journal: British journal of haematology
  • Treatment Used: Idelalisib (IDL) and Rituximab (R)
  • Number of Patients: 110
  • Published —
This study evaluated the outcomes of idelalisib (IDL) and rituximab (R) in the treatment of patients with chronic lymphocytic leukemia (CLL) in the UK and Ireland.
  • Journal: Frontiers in immunology
  • Published —
Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.
  • Journal: Annals of hematology
  • Published —
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
  • Journal: Blood cancer journal
  • Published —
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
  • Condition: COVID-19
  • Journal: Frontiers in immunology
  • Treatment Used: Convalescent Plasma Therapy
  • Number of Patients: 1
  • Published —
This case report describes a patient with COVID-19 ho was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and concomitant chemotherapy for chronic lymphoid leukemia treated with convalescent plasma therapy.
  • Condition: Chronic Lymphocytic Leukemia (CLL)
  • Journal: Blood cancer journal
  • Treatment Used: Ibrutinib Combinations
  • Number of Patients: 0
  • Published —
This article discusses the results of ibrutinib combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).
  • Journal: Blood advances
  • Published —
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.
  • Journal: Medicine
  • Published —
Primary varicella-zoster virus infection of the immunocompromised associated with acute pancreatitis and hemophagocytic lymphohistiocytosis: A case report.
  • Condition: Hematological Malignancies
  • Journal: Scientific reports
  • Treatment Used: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
  • Number of Patients: 3
  • Published —
These case reports describe patients who acquired distinct, severe immune-mediated peripheral or central nervous system diseases after allogeneic hematopoietic stem cell transplantation (alloHSCT) for the treatment of hematological malignancies (blood and bone cancers).
Showing 1-12 of 231